Grifols (GRFS) Cash & Current Investments (2009 - 2025)
Grifols' (GRFS) quarterly Cash & Current Investments came in at $51.2 million in Q4 2025, down 96.07% YoY from $1.3 billion in Q4 2024, and down 96.07% on a QoQ basis from $1.3 billion in Q4 2024.
Grifols (GRFS) Cash & Current Investments (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Cash & Current Investments data on file, last reported at $51.2 million in Q4 2025.
- Quarterly Cash & Current Investments fell 96.07% year-over-year to $51.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $51.2 million (down 96.07% YoY) and the FY2025 annual result came in at $51.2 million, down 96.07% from the prior year.
- Cash & Current Investments declined to $51.2 million in Q4 2025, from $1.3 billion in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $3.1 billion in Q4 2021 to a low of $51.2 million in Q4 2025.
- A 5-year average of $1.1 billion and a median of $604.7 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2021 — Cash & Current Investments surged 335.16% — and 2025, when it plunged 96.07%.
- Tracing GRFS's Cash & Current Investments over 5 years: stood at $3.1 billion in 2021, then sank by 80.27% to $604.7 million in 2022, then decreased by 1.66% to $594.6 million in 2023, then soared by 119.07% to $1.3 billion in 2024, then sank by 96.07% to $51.2 million in 2025.
- The last three Cash & Current Investments figures came in at $51.2 million (Q4 2025), $1.3 billion (Q4 2024), and $594.6 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 4.17 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 1.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.22 Mn |
| Dec 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 594.61 Mn |
| Dec 31, 2022 | 604.66 Mn |
| Dec 31, 2021 | 3.07 Bn |
| Dec 31, 2020 | 704.36 Mn |
| Sep 30, 2020 | 1.22 Bn |
| Mar 31, 2020 | 718.37 Mn |
| Dec 31, 2019 | 210.85 Mn |
| Sep 30, 2019 | 884.51 Mn |
| Mar 31, 2019 | 858.09 Mn |
| Dec 31, 2018 | 1.24 Bn |
| Sep 30, 2018 | 736.73 Mn |
| Jun 30, 2018 | 320.61 Mn |
| Mar 31, 2018 | 1.05 Bn |
| Dec 31, 2017 | 1.06 Bn |
| Jun 30, 2017 | 2.98 Bn |
| Dec 31, 2016 | 969.15 Mn |
| Sep 30, 2016 | 561.51 Mn |
| Jun 30, 2016 | 1.28 Bn |